The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease
ScienceofParkinsons on Twitter: "The study explores data from 145 #Parkinsons clinical trials that were ongoing during 2019-2020, breaking them down into phase & agent type to give the PD community a broad
First-in-class vaccine against IDO and PD-L1 enhances anti-PD-1 in phase I/II clinical trial
The EJS ACT-PD Initiative, Accelerating Clinical Trials in Parkinson's; Dr Camille Carroll - YouTube
Home
Trends in clinical development for PD-1/PD-L1 inhibitors
Pharmaceuticals | Free Full-Text | Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update | HTML
PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials - Journal of Thoracic Oncology
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis - The Lancet Oncology
How genetic testing can help advance clinical trials for Parkinson's disease
China's Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials :: Pink Sheet
ScienceofParkinsons on Twitter: "Interesting analysis & discussion on clinical trial matters like enrollment, sponsors, trials sites, biomarkers, & geography. Plus what the category definition "disease modifying" actually means in #Parkinsons https://t ...
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials | Journal of Hematology & Oncology | Full Text
China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData - GlobalData
Clinical Trials of Parkinson's Disease | Encyclopedia MDPI
Parkinson's Disease Clinical Trial Solutions from Cogstate - Cogstate
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Pharmacodynamic Biomarker Testing - Almac
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Annual Report on Clinical Trials for New Drug Registration in China (2020) - Tigermed
Home
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | SpringerLink
Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma – Ronny Allan – Living with Neuroendocrine Cancer
Role of Phase 0 trials in drug development | Future Medicinal Chemistry
PD Trial Simulation | Critical Path Institute
